Literature DB >> 15613435

Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.

John S Bevan1.   

Abstract

Somatostatin analogs are the mainstay of medical therapy for acromegaly. Suppression of GH hypersecretion, lowering of IGF-I production, and control of symptoms are established benefits of therapy. In addition, clinically significant tumor shrinkage has been seen in a number of studies, particularly in patients undergoing primary medical therapy. This review summarizes current knowledge of the effects of somatostatin analogs on tumor size and cellular morphology and examines the available data on predictors of tumor shrinkage.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15613435     DOI： 10.1210/jc.2004-1093

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


  65 in total

1.  Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.

Authors:  A P Casarini; E M Pinto; R S Jallad; R R Giorgi; D Giannella-Neto; M D Bronstein
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

2.  First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group.

Authors:  A Colao; E Martino; P Cappabianca; R Cozzi; M Scanarini; E Ghigo
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

3.  The manifesto A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) study group one year later: what to keep and what to amend?

Authors:  A Colao; E Ghigo
Journal:  J Endocrinol Invest       Date:  2007-12       Impact factor: 4.256

Review 4.  Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.

Authors:  Gherardo Mazziotti; Andrea Giustina
Journal:  Pituitary       Date:  2010       Impact factor: 4.107

Review 5.  Update on prognostic factors in acromegaly: Is a risk score possible?

Authors:  E Fernandez-Rodriguez; F F Casanueva; I Bernabeu
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

Review 6.  T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective.

Authors:  Iulia Potorac; Albert Beckers; Jean-François Bonneville
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

7.  Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells.

Authors:  B Mariniello; I Finco; P Sartorato; A Patalano; M Iacobone; V Guzzardo; A Fassina; F Mantero
Journal:  J Endocrinol Invest       Date:  2010-10-27       Impact factor: 4.256

Review 8.  Pegvisomant in acromegaly: why, when, how.

Authors:  A Colao; G Arnaldi; P Beck-Peccoz; S Cannavò; R Cozzi; E degli Uberti; L De Marinis; E De Menis; D Ferone; V Gasco; A Giustina; S Grottoli; G Lombardi; P Maffei; E Martino; F Minuto; R Pivonello; E Ghigo
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

Review 9.  The role of combination medical therapy in the treatment of acromegaly.

Authors:  Dawn Shao Ting Lim; Maria Fleseriu
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 10.  Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.

Authors:  A Giustina; A Barkan; P Chanson; A Grossman; A Hoffman; E Ghigo; F Casanueva; A Colao; S Lamberts; M Sheppard; S Melmed
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.